These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
94 related articles for article (PubMed ID: 20502320)
1. Canadian external quality assurance program for breast cancer biomarkers. Terry J; Torlakovic E; Trotter M; Garratt J; Barnes P; Gown A; Pettigrew N; Gilks CB Appl Immunohistochem Mol Morphol; 2010 Oct; 18(5):486. PubMed ID: 20502320 [No Abstract] [Full Text] [Related]
2. Implementation of a Canadian external quality assurance program for breast cancer biomarkers. Flynn GJ; Schirripa C Appl Immunohistochem Mol Morphol; 2010 May; 18(3):299. PubMed ID: 20048673 [No Abstract] [Full Text] [Related]
3. Implementation of a Canadian external quality assurance program for breast cancer biomarkers: an initiative of Canadian Quality Control in immunohistochemistry (cIQc) and Canadian Association of Pathologists (CAP) National Standards Committee/Immunohistochemistry. Terry J; Torlakovic EE; Garratt J; Miller D; Köbel M; Cooper J; Bahzad S; Pilavdzic D; O'Malley F; O'Brien AE; SenGupta S; Alport E; Têtu B; Knight B; Pettigrew NM; Berendt R; Wolber R; Trotter MJ; Riddell RH; Gaboury L; Elms F; Magliocco A; Barnes P; Gown AM; Gilks CB Appl Immunohistochem Mol Morphol; 2009 Oct; 17(5):375-82. PubMed ID: 19363444 [TBL] [Abstract][Full Text] [Related]
4. MIB-1 Cell membrane reactivity: a finding that should be interpreted carefully. Del Sordo R; Sidoni A Appl Immunohistochem Mol Morphol; 2008 Dec; 16(6):568. PubMed ID: 18800001 [No Abstract] [Full Text] [Related]
5. Consensus recommendations on estrogen receptor testing in breast cancer by immunohistochemistry. Yaziji H; Taylor CR; Goldstein NS; Dabbs DJ; Hammond EH; Hewlett B; Floyd AD; Barry TS; Martin AW; Badve S; Baehner F; Cartun RW; Eisen RN; Swanson PE; Hewitt SM; Vyberg M; Hicks DG; Appl Immunohistochem Mol Morphol; 2008 Dec; 16(6):513-20. PubMed ID: 18931614 [TBL] [Abstract][Full Text] [Related]
6. Pathological examination of breast cancer biomarkers: current status in Japan. Masuda S Breast Cancer; 2016 Jul; 23(4):546-51. PubMed ID: 25239167 [TBL] [Abstract][Full Text] [Related]
7. Incorporating microarray assessment of HER2 status in clinical practice supports individualised therapy in early-stage breast cancer. Grant KA; Pienaar FM; Brundyn K; Swart G; Gericke GS; Myburgh EJ; Wright CA; Apffelstaedt JP; Kotze MJ Breast; 2015 Apr; 24(2):137-42. PubMed ID: 25586984 [TBL] [Abstract][Full Text] [Related]
8. Impact of progesterone receptor semiquantitative immunohistochemical result on Oncotype DX recurrence score: a quality assurance study of 1074 cases. Clark BZ; Dabbs DJ; Cooper KL; Bhargava R Appl Immunohistochem Mol Morphol; 2013 Jul; 21(4):287-91. PubMed ID: 23060300 [TBL] [Abstract][Full Text] [Related]
9. Intratumoral heterogeneity of immunohistochemical marker expression in breast carcinoma: a tissue microarray-based study. Nassar A; Radhakrishnan A; Cabrero IA; Cotsonis GA; Cohen C Appl Immunohistochem Mol Morphol; 2010 Oct; 18(5):433-41. PubMed ID: 20485156 [TBL] [Abstract][Full Text] [Related]
10. Quality assurance in immunohistochemistry. Rhodes A Am J Surg Pathol; 2003 Sep; 27(9):1284-5; author reply 1285-6. PubMed ID: 12960815 [No Abstract] [Full Text] [Related]
11. Academic and nonacademic laboratories perform equally on CIQC immunohistochemistry proficiency testing. Chen ZW; Neufeld H; Copete MA; Garratt J; Gilks CB; Torlakovic EE Am J Clin Pathol; 2013 Jul; 140(1):55-60. PubMed ID: 23765534 [TBL] [Abstract][Full Text] [Related]
12. Understanding the age dependency of breast cancer biomarkers. Benz CC; Thor AD; Eppenberger-Castori S; Eppenberger U; Moore D Adv Gerontol; 2003; 11():117-20. PubMed ID: 12820531 [TBL] [Abstract][Full Text] [Related]
13. Is initially metastatic breast carcinoma different from recurrent metastatic breast carcinoma? Dizdar O; Aksoy S; Altundag K Ann Oncol; 2009 Jan; 20(1):189; author reply 189-90. PubMed ID: 18820244 [No Abstract] [Full Text] [Related]
14. Virtual slide telepathology enables an innovative telehealth rapid breast care clinic. López AM; Graham AR; Barker GP; Richter LC; Krupinski EA; Lian F; Grasso LL; Miller A; Kreykes LN; Henderson JT; Bhattacharyya AK; Weinstein RS Hum Pathol; 2009 Aug; 40(8):1082-91. PubMed ID: 19552938 [TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical profile of breast cancer with respect to estrogen receptor and HER2 status. Gloyeske NC; Woodard AH; Elishaev E; Yu J; Clark BZ; Dabbs DJ; Bhargava R Appl Immunohistochem Mol Morphol; 2015 Mar; 23(3):202-8. PubMed ID: 25356941 [TBL] [Abstract][Full Text] [Related]
16. The Impact of Ki-67 on Immunostaining in Classification of Luminal Subtypes of breast Cancer. Lagios MD Breast J; 2015; 21(5):463-4. PubMed ID: 26332073 [No Abstract] [Full Text] [Related]
17. Distinguishing score 0 from score 1+ in HER2 immunohistochemistry-negative breast cancer: clinical and pathobiological relevance. Lambein K; Van Bockstal M; Vandemaele L; Geenen S; Rottiers I; Nuyts A; Matthys B; Praet M; Denys H; Libbrecht L Am J Clin Pathol; 2013 Oct; 140(4):561-6. PubMed ID: 24045554 [TBL] [Abstract][Full Text] [Related]
18. [Quality assured HER2 analysis in breast cancer. Important therapeutic predictive and prognostic factor]. Fernö M; Haglund M; Bendahl PO; Olsson H; Rydén L Lakartidningen; 2008 Aug 6-19; 105(32-33):2181-4. PubMed ID: 18780693 [No Abstract] [Full Text] [Related]
19. Delayed diagnosis of breast cancer. Int J Qual Health Care; 1998 Dec; 10(6):561. PubMed ID: 9928596 [No Abstract] [Full Text] [Related]
20. Application of tissue microarrays for receptor immunohistochemistry in breast carcinoma. Glajcar A; Kaczmarczyk K; Szpor J; Okon K Folia Histochem Cytobiol; 2013; 51(4):326-32. PubMed ID: 24497138 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]